Legend Biotech Corporation (FRA:9LB)
Germany · Delayed Price · Currency is EUR 30.00
+8.40 (38.89%)
Last updated: Jun 3, 2026, 7:55 PM CET
Legend Biotech Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,139 | 1,029 | 627.3 | 285.1 | 117.01 | 68.83 | |
Revenue Growth (YoY) | 56.38% | 64.02% | 120.03% | 143.66% | 70.00% | -8.23% |
Cost of Revenue | 512.7 | 408.1 | 234.6 | 144.2 | 65.36 | - |
Gross Profit | 626.09 | 620.8 | 392.7 | 140.9 | 51.64 | 68.83 |
Selling, General & Admin | 359.27 | 341.6 | 284.3 | 201 | 174.05 | 149.5 |
Research & Development | 398.45 | 414.7 | 413.5 | 382.2 | 335.65 | 313.35 |
Other Operating Expenses | 3.2 | 1 | 4.4 | 85.8 | -23.13 | 12.27 |
Operating Income | -112.95 | -136.5 | -309.5 | -528.1 | -434.93 | -406.3 |
Interest Income | 35.29 | 40.1 | 61.2 | 54.5 | - | - |
Interest Expense | -21.86 | -21.4 | -21.6 | -21.8 | -10.8 | -0.9 |
Other Non-Operating Income (Expense) | -115.27 | -164.8 | 111.8 | -24.8 | - | - |
Total Non-Operating Income (Expense) | -101.84 | -146.1 | 151.4 | 7.9 | -10.8 | -0.9 |
Pretax Income | -236.67 | -282.6 | -158.1 | -520.2 | -445.72 | -407.2 |
Provision for Income Taxes | 13.6 | 14.2 | 18.9 | -1.9 | 0.63 | -3.61 |
Net Income | -250.27 | -296.8 | -177 | -518.3 | -446.35 | -403.58 |
Net Income to Common | -250.27 | -296.8 | -177 | -518.3 | -446.35 | -403.58 |
Shares Outstanding (Basic) | 185 | 184 | 183 | 176 | 159 | 141 |
Shares Outstanding (Diluted) | 185 | 184 | 183 | 176 | 159 | 141 |
Shares Change (YoY) | -1.65% | 0.80% | 3.84% | 10.71% | 12.91% | 19.21% |
EPS (Basic) | -1.36 | -1.62 | -0.96 | -2.94 | -2.80 | -2.86 |
EPS (Diluted) | -1.36 | -1.62 | -0.96 | -2.94 | -2.80 | -2.86 |
Shares Outstanding | 185.74 | 184.94 | 183.65 | 181.91 | 165.07 | 154.23 |
Free Cash Flow | -115.8 | -128.8 | -158.1 | -413.4 | -222.21 | -240.66 |
Free Cash Flow Per Share | -0.63 | -0.70 | -0.86 | -2.35 | -1.40 | -1.71 |
Gross Margin | 54.98% | 60.34% | 62.60% | 49.42% | 44.14% | 100.00% |
Operating Margin | -9.92% | -13.27% | -49.34% | -185.23% | -371.72% | -590.32% |
Profit Margin | -21.98% | -28.85% | -28.22% | -181.80% | -381.48% | -586.38% |
FCF Margin | -10.17% | -12.52% | -25.20% | -145.00% | -189.91% | -349.67% |
EBITDA | -73.44 | -107.6 | -288.1 | -509.6 | -416.54 | -392.38 |
EBITDA Margin | -6.45% | -10.46% | -45.93% | -178.74% | -356.00% | -570.10% |
EBIT | -112.95 | -136.5 | -309.5 | -528.1 | -434.93 | -406.3 |
EBIT Margin | -9.92% | -13.27% | -49.34% | -185.23% | -371.72% | -590.32% |
Effective Tax Rate | -5.75% | -5.02% | -11.95% | 0.37% | -0.14% | 0.89% |